HDCN Abstract:  ASN Annual Meeting 2020 -- Digital Meeting  

Hamroun A, Antoine D, Blum D, et al.

Daily Caffeine Consumption and Risk of AKI Related to Platinum-Salt Chemotherapy: A Prospective Cohort Study

ASN Annual Meeting 2020 -- Digital Meeting
J Am Soc Nephrol (Oct) 31:10A 2020


Although their efficacy has been well-established in Oncology, the use of platinum salts remains limited due to the occurrence of acute kidney injury (AKI). Caffeine has been suggested as a potential pathophysiological actor of platinum salt-induced AKI, through its hemodynamic effects. This work aims to study the association between caffeine consumption and the risk of platinum salt-induced AKI.


We conducted a single-center prospective cohort study that has included 108 consecutive thoracic cancer patients receiving a first-line platinum-salt chemotherapy between January 2017 and December 2018. Before the first course of chemotherapy, they were all invited to fill in a previously validated auto-questionnaire, designed for a detailed evaluation of their daily caffeine consumption (mg/day). The association of daily caffeine consumption with the risk of platinum-salt induced AKI was estimated by cause-specific Cox proportional hazard model adjusted for several known confounders (baseline renal function and serum albumin level, nature and dose of platinum-salt, tobacco exposure, and Performans status).


Overall, 34 patients (31.5%) (mean age 61.7 years, 65% men, 80% tobacco users) experienced a platinum salt-induced AKI (67% grade 1) and 47 (43.5%) died during follow-up (6.2 months [3.4; 8.4]). The group of high-caffeine consumption (≥ 386mg/day) had a twice higher risk of AKI (HR=2.12 [1.01; 4.45]) in the fully adjusted model. The cumulative incidence of AKI (considering the competing risk of death) was also significantly increased in the high-caffeine consumption group (p=0.03, see figure 1).


In a population of thoracic cancer patients, the group of high-caffeine consumption was exposed to a significantly higher risk of platinum salt-induced AKI.

© Copyright 2020 -2021 American Society of Nephrology. Reproduced with permission.

All ASN abstracts from the 2020 Annual Meeting are available at this link and also are archived in .pdf form at ASN-Online.org

Disclaimer: Abstracts often have errors, both typographical and otherwise. This posting is an electronic translation of submitted abstracts which has not been verified against the original submitted abstract nor with the authors for accuracy. As a result, there may be errors, especially with regard to drug doses, but not limited to these. Abstracts undergo only limited review, and data often are changed as a result of the peer review process, so their reliability is less than manuscripts published in peer-reviewed journals. In using these summaries, you are agreeing that you are aware of these limitations.

The materials are provided on an as-is basis without any warranty of any kind, either express or implied. In addition to errors, the information presented may be incomplete or outdated. The information contained is not intended nor recommended as a substitute for professional medical advice. You are advised to check the appropriate medical literature and the product information currently provided by the manufacturer of each device to be used or drug to be administered to verify the dosage, the method and duration of administration, or contraindications. It is the responsibility of the treating physician or other health care professional, relying on independent experience and knowledge of the patient, to determine drug, disease, and the best treatment for the patient.

To the fullest extent permitted by law, HDCN, ASN and their affiliates and suppliers disclaim all warranties, express or implied, including, but not limited to, any warranty of merchantability, non- infringement or fitness for a particular purpose.

In no event shall HDCN, ASN, or their affiliates or suppliers be liable for any damages whatsoever (including, but not limited to, direct, indirect, incidental, consequential, punitive or exemplary damages, or any damages for loss of profits, use, data, goodwill or other intangibles) arising from or in any way relating to these terms, the materials, or any information, goods or services obtained from or referred to in the materials, whether based on warranty, contract, tort (including, but not limited to, negligence), or any other legal theory, and whether or not any or all of the limited entities is advised of the possibility of such damages.